Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Charalambos Andreadis et al.|Clinical Cancer Research|2019Cited by 40
Table and Fig from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Unknown|2023Cited by 0
Data from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Unknown|2023Cited by 0
Data from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Unknown|2023Cited by 0
Table and Fig from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Unknown|2023Cited by 0